Quick Answer
Marker Therapeutics, Inc. reported Diluted EPS of $0.79 per share (loss) for fiscal year 2025.
Marker Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.79 | +33.6% |
| 2024 | -$1.19 | -26.6% |
| 2023 | -$0.94 | +73.7% |
| 2022 | -$3.58 | +34.6% |
| 2021 | -$5.47 | -796.7% |
| 2020 | -$0.61 | +47.4% |
| 2017 | -$1.16 | -61.1% |
| 2016 | -$0.72 | +92.3% |
| 2015 | -$9.30 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.12 | +53.8% | +58.6% |
| June 30, 2025 | -$0.29 | -16.0% | +27.5% |
| March 31, 2025 | -$0.40 | -48.1% | -53.8% |
| September 30, 2024 | -$0.26 | +23.5% | -4.0% |
| June 30, 2024 | -$0.25 | -186.2% | +7.4% |
| March 31, 2024 | -$0.27 | +52.6% | +20.6% |
| September 30, 2023 | -$0.34 | +59.0% | -217.2% |
| June 30, 2023 | $0.29 | +126.1% | +150.9% |
- Marker Therapeutics, Inc. showed an increase of +33.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2015–2025 period, Marker Therapeutics, Inc.’s diluted eps has grown by 91.5% (from $9.30 per share (loss) to $0.79 per share (loss)).
- The most recent figure is from Marker Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: